alexa Antimutagenic and Anticarcinogenic Activity of Emblica oficinalis Gaertn
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Diabetes & Metabolism

Author(s): Jeena K, JOSE, Girija KUTTAN, Josely GEORG, Ramadasan KUTTAN

Abstract Share this page

Summary Aqueous extracts of Emblica offrcinalis and Chyavanaprash, an indigenous drug preparation in which Emblica officinalis is a major ingredient, were found to inhibit 20-methylcholanthrene-induced sarcoma and to increase the life span of the animals. Oral administration of Emblica (10 mg/mice) and Chyavanaprash (50 mg/mice) extracts produced a 75% reduction in the development of sarcoma. The aqueous extract of Emblica was also found to inhibit the activation and mutagenicity of 2-acetamidofluorene (2-AAF) as well as that of direct-acting mutagens N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and 4-nitro-Ophenylenediamine (4-NPDA). The extract was found to inhibit microsomal P-450 enzyme, aniline hydroxylase. The activity of the extract may be mainly related to its oxygen radical-scavenging activity as well as to inhibition of Phase-I enzymes

  • To read the full article Visit
  • Subscription
This article was published in J. Clin. Biochem. Nutr., and referenced in Journal of Diabetes & Metabolism

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version